Bismuth Subcitrate+Metronidazole+Tetracycline

DRUG INFORMATION

  ADULT
    - One omeprazole 20 mg capsule should be taken twice a day with bismuth subcitrate
      potassium, metronidazole and tetracycline hydrochloride capsules after the morning
      and evening meal for 10 days ( Table 1 ).
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for bismuth subcitrate
      (Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride),
      section 'dosage and administration', retrieved 2026-08-29
    - ( 2 ) Administer bismuth subcitrate potassium, metronidazole and tetracycline
      hydrochloride capsules with omeprazole 20 mg twice daily (after the morning and
      evening meals).
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'dosage and
      administration', retrieved 2026-08-29
    - Administer three bismuth subcitrate potassium, metronidazole and tetracycline
      hydrochloride capsules 4 times a day (after meals and at bedtime) for 10 days. One
      omeprazole 20 mg capsule should be taken twice a day with bismuth subcitrate
      potassium, metronidazole and tetracycline hydrochloride capsules after the morning
      and evening meal for 10 days ( Table 1 ).
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for bismuth subcitrate
      (Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride),
      section 'dosage and administration', retrieved 2026-08-29

  CHILD
    - No child dose in this label. That usually means untested in children, not
      unsuitable - use a paediatric source.
      Source: Read and found silent: the US FDA label for bismuth subcitrate (Bismuth
      Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride), retrieved
      2026-08-29

  RENAL IMPAIRMENT
    - Because elderly patients are more likely to have decreased renal function,
      additional monitoring may be required [see Contraindications (4.4) ]. 8.6 Renal
      Impairment The antianabolic action of the tetracyclines may cause an increase in
      blood urea nitrogen (BUN).
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'use in specific
      populations', retrieved 2026-08-29
    - In patients with severe renal impairment, higher serum concentrations of
      tetracycline may lead to azotemia, hyperphosphatemia, and acidosis [see
      Contraindications (4.4) ]. 8.7 Hepatic Impairment Patients with severe hepatic
      disease metabolize metronidazole slowly, with resultant accumulation of
      metronidazole and its metabolites in plasma.
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'use in specific
      populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - In patients with severe renal impairment, higher serum concentrations of
      tetracycline may lead to azotemia, hyperphosphatemia, and acidosis [see
      Contraindications (4.4) ]. 8.7 Hepatic Impairment Patients with severe hepatic
      disease metabolize metronidazole slowly, with resultant accumulation of
      metronidazole and its metabolites in plasma.
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'use in specific
      populations', retrieved 2026-08-29
    - Patients with mild to moderate hepatic impairment should be monitored for
      metronidazole associated adverse events.
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'use in specific
      populations', retrieved 2026-08-29
    - Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride is not
      recommended in patients with severe hepatic impairment [see Warnings and
      Precautions (5.11) and Clinical Pharmacology (12.3) ].
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY
    - Administration of oral tetracycline to pregnant rats at various doses resulted in
      yellow fluorescence in teeth and bones in the newborn animals.
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'pregnancy', retrieved
      2026-08-29
    - There are maternal risks with high intravenous doses of tetracycline [see Clinical
      Considerations].
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'pregnancy', retrieved
      2026-08-29
    - Metronidazole usage in pregnancy has been associated with certain congenital
      anomalies [see Data].
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Safety and effectiveness of bismuth subcitrate potassium, metronidazole and
      tetracycline hydrochloride in pediatric patients infected with Helicobacter pylori
      have not been established.
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'nursing mothers',
      retrieved 2026-08-29
    - Tetracycline use in children may cause permanent discoloration of the teeth.
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'nursing mothers',
      retrieved 2026-08-29
    - Enamel hypoplasia has also been reported.
      Source: US FDA label for bismuth subcitrate (Bismuth Subcitrate Potassium,
      Metronidazole and Tetracycline Hydrochloride), section 'nursing mothers',
      retrieved 2026-08-29